Drug intelligence / Profile preview

Classical Swine Fever Vaccine (US Biologic)

Development stage: Preclinical
Lead developer: US Biologic
Modality: Vaccines & Immunotherapeutics
Administration: Oral

Overview

US Biologic's Classical Swine Fever (CSF) vaccine is an oral vaccine candidate developed using the proprietary OrisBio platform. This platform utilizes *Bacillus subtilis* (*B. subtilis*) spores as a delivery vehicle to express Classical Swine Fever Virus (CSFV) antigens. Upon oral administration, these spores are designed to induce protective mucosal and systemic immunity in swine. The program is being developed in collaboration with the Department of Homeland Security (DHS) Plum Island Animal Disease Center and is currently in the preclinical stage.

Other names: CSFV oral vaccineOrisBio CSFV vaccineUS Biologic CSFV vaccine

Targets

CSFV (Classical swine fever virus)

Beyond the preview

Go deeper on Classical Swine Fever Vaccine (US Biologic).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Classical Swine Fever Vaccine (US Biologic).

Explore the full profile